Masanori Atsukawa

74PUBLICATIONS
213CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Predictive and prognostic markersHaematologyGene and molecular therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (74)

|Jul 20, 2026
Baseline DCP May Modify Response to Atezolizumab-Bevacizumab Versus Durvalumab-Tremelimumab in Unresectable HCC.

|Jul 16, 2026
Simplified BALAD (BALAD-S) Score as a Guide for First-Line Immune Checkpoint Inhibitor Selection for Unresectable Hepatocellular Carcinoma.

|Jun 26, 2026
Metabolomics Approach Identifies Predictive Serum Markers for Hepatocellular Carcinogenesis Following Hepatitis C Virus Elimination.

|Jun 08, 2026
Validation of Risk Models for Predicting Post-SVR HCC in Real-World Surveillance Across Global Geographic Regions.

|May 23, 2026
Outcomes of Patients With Hepatocellular Carcinoma Treated With Durvalumab Plus Tremelimumab in Real-World Clinical Practice Who Met or Did Not Meet the Inclusion Criteria for the Phase 3 HIMALAYA Trial.

|May 22, 2026
Editorial: Tenofovir Alafenamide Versus Entecavir for Hepatitis B Surface Antigen Decline-A Step Towards Functional Cure or a Marginal Margin? Authors' Reply.

Pageof 13

Frequent Collaborators

44 joint publications

Hidenori Toyoda

35 joint publications

Toshifumi Tada

33 joint publications

Takashi Kumada

31 joint publications

Atsushi Hiraoka